New Zealand markets open in 2 hours 1 minute

REGN May 2024 750.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
4.10000.0000 (0.00%)
As of 02:21PM EST. Market open.
Full screen
Previous close4.1000
Open4.1000
Bid0.0500
Ask6.7000
Strike750.00
Expiry date2024-05-17
Day's range4.1000 - 4.1000
Contract rangeN/A
Volume5
Open interest185
  • GlobeNewswire

    Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

    TARRYTOWN, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for linvoseltamab to treat adult patients with relapsed/refractory (R/R) multiple myeloma (MM) that has progressed after at least three prior therapies. The target action date for the FDA decision is August 22, 2024. Linvoseltamab is an investigational bispecific

  • GlobeNewswire

    Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)

    Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved indication for Dupixent in Japan and the sixth indication for Dupixent globally TARRYTOWN, N.Y. and PARIS, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent® (dupilumab) for the

  • Simply Wall St.

    Possible Bearish Signals With Regeneron Pharmaceuticals Insiders Disposing Stock

    Many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders ditched their stock over the past year, which may be of...